Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for huntington's disease

Journal of Medicinal Chemistry

Volumn 56, Issue 24, 2013, Pages 9934-9954

  Bürli, Roland W ^a   Luckhurst, Christopher A ^a   Aziz, Omar ^a   Matthews, Kim L ^a   Yates, Dawn ^a   Lyons, Kathy A ^c   Beconi, Maria ^c   McAllister, George ^a   Breccia, Perla ^a   Stott, Andrew J ^a   Penrose, Stephen D ^a   Wall, Michael ^a   Lamers, Marieke ^a   Leonard, Philip ^a   Müller, Ilka ^a   Richardson, Christine M ^a   Jarvis, Rebecca ^a   Stones, Liz ^a   Hughes, Samantha ^a   Wishart, Grant ^a   Haughan, Alan F ^a   O'Connell, Catherine ^a   Mead, Tania ^a   McNeil, Hannah ^a   Vann, Julie ^a   Mangette, John ^b   Maillard, Michel ^c   Beaumont, Vahri ^c   Munoz Sanjuan, Ignacio ^c   Dominguez, Celia ^c   more..

^a BioFocus DPI   (United Kingdom)

^b ALBANY MOLECULAR RESEARCH INC   (United States)

^c CHDI MANAGEMENT CHDI FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CYCLOPROPYLPYRIDIN 4 YL) N HYDROXY 3 PHENYLCYCLOPROPANECARBOXAMIDE; 2 (8 CHLORO 2,3 DIHYDROBENZO[B][1,4]DIOXIN-6-YL) N HYDROXY 3 PHENYLCYCLOPROPANECARBOXAMIDE; 2 [3 (5 FLUOROPYRIMIDIN 2 YL)PHENYL] N HYDROXY 3 PHENYLCYCLOPROPANECARBOXAMIDE; 2 [4 (2 CYCLOPROPYLOXAZOL 5 YL)PHENYL] N HYDROXY 3 PHENYLCYCLOPROPANECARBOXAMIDE; 2 [4 (5 FLUOROPYRIMIDIN 2 YL)PHENYL] N HYDROXY 3 PHENYLCYCLOPROPANECARBOXAMIDE; CYCLOPROPANE; HISTONE DEACETYLASE 4 INHIBITOR; HISTONE DEACETYLASE 5 INHIBITOR; HISTONE DEACETYLASE 7 INHIBITOR; HISTONE DEACETYLASE 9 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; N HYDROXY 2 (1 METHYL 1H PYRAZOL 4 YL) 3 PHENYLCYCLOPROPANECARBOXAMIDE; N HYDROXY 2 [1 OXO 2 (2,2,2 TRIFLUOROETHYL)ISOINDOLIN 5 YL] 3 PHENYLCYCLOPROPANECARBOXAMIDE; N HYDROXY 2 [4 (OXAZOL 5 YL)PHENYL] 3 PHENYLCYCLOPROPANECARBOXAMIDE; N HYDROXY 2 PHENYL 3 (QUINOXALIN 6 YL)CYCLOPROPANECARBOXAMIDE; N HYDROXY 2,3 DIPHENYLCYCLOPROPANECARBOXAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALYSIS; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG MUSCLE LEVEL; ENZYME ACTIVE SITE; HUNTINGTON CHOREA; IC 50; MALE; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

EID: 84891304904     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm4011884     Document Type: Article

References (70)

1. Choudhary, C.; Kumar, C.; Gnad, F.; Nielsen, M. L.; Rehman, M.; Walther, T. C.; Olsen, J. V.; Mann, M. Lysine acetylation targets protein complexes and co-regulates major cellular functions Science 2009, 325, 834-840
2. Aka, J. A.; Kim, G. W.; Yang, X. J. K-acetylation and its enzymes: overview and new developments Handb. Exp. Pharmacol. 2011, 206, 1-12
3. McKinsey, T. A. The biology and therapeutic implications of HDACs in the heart Handb. Exp. Pharmacol. 2011, 206, 57-78
4. Grabiec, A. M.; Tak, P. P.; Reedquist, K. A. Function of histone deacetylase inhibitors in inflammation Crit. Rev. Immunol. 2011, 31, 233-263
5. Haggarty, S. J.; Tsai, L. H. Probing the role of HDACs and mechanisms of chromatin-mediated neuroplasticity Neurobiol. Learn. Mem. 2011, 96, 41-52
6. Fischle, W.; Dequiedt, F.; Hendzel, M. J.; Guenther, M. G.; Lazar, M. A.; Voelter, W.; Verdin, E. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR Mol. Cell 2002, 9, 45-57
7. Yang, X. J.; Gregoire, S. Class II histone deacetylases: from sequence to function, regulation, and clinical implication Mol. Cell. Biol. 2005, 25, 2873-2884
8. Verdin, E.; Dequiedt, F.; Kasler, H. G. Class II histone deacetylases: versatile regulators Trends Genet. 2003, 19, 286-293
9. Clocchiatti, A.; Florean, C.; Brancolini, C. Class IIa HDACs: from important roles in differentiation to possible implications in tumourigenesis J. Cell. Mol. Med. 2011, 15, 1833-1846
10. Lahm, A.; Paolini, C.; Pallaoro, M.; Nardi, M. C.; Jones, P.; Neddermann, P.; Sambucini, S.; Bottomley, M. J.; Lo Surdo, P.; Carfi, A.; Koch, U.; De Francesco, R.; Steinkuhler, C.; Gallinari, P. Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 17335-17340
11. Jones, P.; Altamura, S.; De Francesco, R.; Gallinari, P.; Lahm, A.; Neddermann, P.; Rowley, M.; Serafini, S.; Steinkuhler, C. Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases Bioorg. Med. Chem. Lett. 2008, 18, 1814-1819
12. Bradner, J. E.; West, N.; Grachan, M. L.; Greenberg, E. F.; Haggarty, S. J.; Warnow, T.; Mazitschek, R. Chemical phylogenetics of histone deacetylases Nat. Chem. Biol. 2010, 6, 238-243
13. Fischle, W.; Kiermer, V.; Dequiedt, F.; Verdin, E. The emerging role of class II histone deacetylases Biochem. Cell Biol. 2001, 79, 337-348
14. Mihaylova, M. M.; Vasquez, D. S.; Ravnskjaer, K.; Denechaud, P. D.; Yu, R. T.; Alvarez, J. G.; Downes, M.; Evans, R. M.; Montminy, M.; Shaw, R. J. Class IIa histone deacetylases are hormone-activated regulators of FOXO and mammalian glucose homeostasis Cell 2011, 145, 607-621
15. Raichur, S.; Teh, S. H.; Ohwaki, K.; Gaur, V.; Long, Y. C.; Hargreaves, M.; McGee, S. L.; Kusunoki, J. Histone deacetylase 5 regulates glucose uptake and insulin action in muscle cells J. Mol. Endocrinol. 2012, 49, 203-211
16. Ago, T.; Liu, T.; Zhai, P.; Chen, W.; Li, H.; Molkentin, J. D.; Vatner, S. F.; Sadoshima, J. A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy Cell 2008, 133, 978-993
17. Ling, S.; Sun, Q.; Li, Y.; Zhang, L.; Zhang, P.; Wang, X.; Tian, C.; Li, Q.; Song, J.; Liu, H.; Kan, G.; Cao, H.; Huang, Z.; Nie, J.; Bai, Y.; Chen, S.; Li, Y.; He, F.; Zhang, L.; Li, Y. CKIP-1 inhibits cardiac hypertrophy by regulating class II histone deacetylase phosphorylation through recruiting PP2A Circulation 2012, 126, 3028-3040
18. McKinsey, T. A.; Kuwahara, K.; Bezprozvannaya, S.; Olson, E. N. Class II histone deacetylases confer signal responsiveness to the ankyrin-repeat proteins ANKRA2 and RFXANK Mol. Biol. Cell 2006, 17, 438-447
19. McKinsey, T. A.; Olson, E. N. Dual roles of histone deacetylases in the control of cardiac growth Novartis Found. Symp. 2004, 259, 132-141 (discussion 141-145, 163-169)
20. Kee, H. J.; Kook, H. Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy J. Biomed. Biotechnol. 2011, 2011, 928326
21. Kong, Y.; Tannous, P.; Lu, G.; Berenji, K.; Rothermel, B. A.; Olson, E. N.; Hill, J. A. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy Circulation 2006, 113, 2579-2588
22. Matsushima, S.; Kuroda, J.; Ago, T.; Zhai, P.; Park, J. Y.; Xie, L. H.; Tian, B.; Sadoshima, J. Increased oxidative stress in the nucleus caused by Nox4 mediates oxidation of HDAC4 and cardiac hypertrophy Circ. Res. 2013, 112, 651-663
23. Granger, A.; Abdullah, I.; Huebner, F.; Stout, A.; Wang, T.; Huebner, T.; Epstein, J. A.; Gruber, P. J. Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice FASEB J. 2008, 22, 3549-3560
24. Hancock, W. W.; Akimova, T.; Beier, U. H.; Liu, Y.; Wang, L. HDAC inhibitor therapy in autoimmunity and transplantation Ann. Rheum. Dis. 2012, 71 (Suppl. 2) i46-i54
25. de Zoeten, E. F.; Wang, L.; Sai, H.; Dillmann, W. H.; Hancock, W. W. Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice Gastroenterology 2010, 138, 583-594
26. Mannaerts, I.; Eysackers, N.; Onyema, O. O.; Van Beneden, K.; Valente, S.; Mai, A.; Odenthal, M.; van Grunsven, L. A. Class II HDAC inhibition hampers hepatic stellate cell activation by induction of MicroRNA-29 PLoS One 2013, 8, e55786
27. Mielcarek, M.; Benn, C. L.; Franklin, S. A.; Smith, D. L.; Woodman, B.; Marks, P. A.; Bates, G. P. SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease PLoS One 2011, 6, e27746
28. Mielcarek, M.; Landles, C.; Weiss, A.; Bradaia, A.; Seredenina, T.; Inuabasi, L.; Osborne, G. F.; Wadel, K.; Touller, C.; Butler, R.; Robertson, J.; Franklin, S. A.; Smith, D. L.; Park, L.; Marks, P. A.; Wanker, E. E.; Olson, E. N.; Luthi-Carter, R.; van der Putten, H.; Beaumont, V.; Bates, G. P. HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration. PLoS Biol., submitted.
29. Sung, Y. M.; Lee, T.; Yoon, H.; DiBattista, A. M.; Song, J. M.; Sohn, Y.; Moffat, E. I.; Turner, R. S.; Jung, M.; Kim, J.; Hoe, H. S. Mercaptoacetamide-based class II HDAC inhibitor lowers Abeta levels and improves learning and memory in a mouse model of Alzheimer's disease Exp. Neurol. 2013, 239, 192-201
30. Hobara, T.; Uchida, S.; Otsuki, K.; Matsubara, T.; Funato, H.; Matsuo, K.; Suetsugi, M.; Watanabe, Y. Altered gene expression of histone deacetylases in mood disorder patients J. Psychiatr. Res. 2010, 44, 263-270
31. Iga, J.; Ueno, S.; Yamauchi, K.; Numata, S.; Kinouchi, S.; Tayoshi-Shibuya, S.; Song, H.; Ohmori, T. Altered HDAC5 and CREB mRNA expressions in the peripheral leukocytes of major depression Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31, 628-632
32. Renthal, W.; Maze, I.; Krishnan, V.; Covington, H. E., 3rd; Xiao, G.; Kumar, A.; Russo, S. J.; Graham, A.; Tsankova, N.; Kippin, T. E.; Kerstetter, K. A.; Neve, R. L.; Haggarty, S. J.; McKinsey, T. A.; Bassel-Duby, R.; Olson, E. N.; Nestler, E. J. Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli Neuron 2007, 56, 517-529
33. Tsankova, N.; Renthal, W.; Kumar, A.; Nestler, E. J. Epigenetic regulation in psychiatric disorders Nat. Rev. Neurosci. 2007, 8, 355-367
34. Tsankova, N. M.; Berton, O.; Renthal, W.; Kumar, A.; Neve, R. L.; Nestler, E. J. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action Nat. Neurosci. 2006, 9, 519-525
35. Cohen, T. J.; Barrientos, T.; Hartman, Z. C.; Garvey, S. M.; Cox, G. A.; Yao, T. P. The deacetylase HDAC4 controls myocyte enhancing factor-2-dependent structural gene expression in response to neural activity FASEB J. 2009, 23, 99-106
36. Simmons, B. J.; Cohen, T. J.; Bedlack, R.; Yao, T. P. HDACs in skeletal muscle remodeling and neuromuscular disease Handb. Exp. Pharmacol. 2011, 206, 79-101
37. Chen, J. F.; Mandel, E. M.; Thomson, J. M.; Wu, Q.; Callis, T. E.; Hammond, S. M.; Conlon, F. L.; Wang, D. Z. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation Nat. Genet. 2006, 38, 228-233
38. Williams, A. H.; Valdez, G.; Moresi, V.; Qi, X.; McAnally, J.; Elliott, J. L.; Bassel-Duby, R.; Sanes, J. R.; Olson, E. N. MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice Science 2009, 326, 1549-1554
39. Choi, M. C.; Cohen, T. J.; Barrientos, T.; Wang, B.; Li, M.; Simmons, B. J.; Yang, J. S.; Cox, G. A.; Zhao, Y.; Yao, T. P. A direct HDAC4-MAP kinase crosstalk activates muscle atrophy program Mol. Cell 2012, 47, 122-132
40. Hebach, C.; Kallen, J.; Nozulak, J.; Tintelnot-Blomley, M.; Widler, L. Novel Trifluoromethyl-oxadiazole Derivatives and Their Use in the Treatment of Disease. WO 2013/080120, June 6, 2013.
41. Beconi, M.; Aziz, O.; Matthews, K.; Moumne, L.; O'Connell, C.; Yates, D.; Clifton, S.; Pett, H.; Vann, J.; Crowley, L.; Haughan, A. F.; Smith, D. L.; Woodman, B.; Bates, G. P.; Brookfield, F.; Burli, R. W.; McAllister, G.; Dominguez, C.; Munoz-Sanjuan, I.; Beaumont, V. Oral administration of the pimelic diphenylamide HDAC inhibitor HDACi 4b is unsuitable for chronic inhibition of HDAC activity in the CNS in vivo PLoS One 2012, 7, e44498
42. Hoffmann, K.; Brosch, G.; Loidl, P.; Jung, M. A non-isotopic assay for histone deacetylase activity Nucleic Acids Res. 1999, 27, 2057-2058
43. Ciossek, T.; Julius, H.; Wieland, H.; Maier, T.; Beckers, T. A homogeneous cellular histone deacetylase assay suitable for compound profiling and robotic screening Anal. Biochem. 2008, 372, 72-81
44. Riester, D.; Wegener, D.; Hildmann, C.; Schwienhorst, A. Members of the histone deacetylase superfamily differ in substrate specificity towards small synthetic substrates Biochem. Biophys. Res. Commun. 2004, 324, 1116-1123
45. Bottomley, M. J.; Lo Surdo, P.; Di Giovine, P.; Cirillo, A.; Scarpelli, R.; Ferrigno, F.; Jones, P.; Neddermann, P.; De Francesco, R.; Steinkuhler, C.; Gallinari, P.; Carfi, A. Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain J. Biol. Chem. 2008, 283, 26694-26704
46. Jones, P.; Bottomley, M. J.; Carfi, A.; Cecchetti, O.; Ferrigno, F.; Lo Surdo, P.; Ontoria, J. M.; Rowley, M.; Scarpelli, R.; Schultz-Fademrecht, C.; Steinkuhler, C. 2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors Bioorg. Med. Chem. Lett. 2008, 18 (141-145) 163-169
47. Muraglia, E.; Altamura, S.; Branca, D.; Cecchetti, O.; Ferrigno, F.; Orsale, M. V.; Palumbi, M. C.; Rowley, M.; Scarpelli, R.; Steinkuhler, C.; Jones, P. 2-Trifluoroacetylthiophene oxadiazoles as potent and selective class II human histone deacetylase inhibitors Bioorg. Med. Chem. Lett. 2008, 18, 6083-6087
48. Tessier, P.; Smil, D. V.; Wahhab, A.; Leit, S.; Rahil, J.; Li, Z.; Deziel, R.; Besterman, J. M. Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 5684-5688
49. Ontoria, J. M.; Altamura, S.; Di Marco, A.; Ferrigno, F.; Laufer, R.; Muraglia, E.; Palumbi, M. C.; Rowley, M.; Scarpelli, R.; Schultz-Fademrecht, C.; Serafini, S.; Steinkuhler, C.; Jones, P. Identification of novel, selective, and stable inhibitors of class II histone deacetylases. Validation studies of the inhibition of the enzymatic activity of HDAC4 by small molecules as a novel approach for cancer therapy J. Med. Chem. 2009, 52, 6782-6789
50. Mai, A.; Massa, S.; Pezzi, R.; Simeoni, S.; Rotili, D.; Nebbioso, A.; Scognamiglio, A.; Altucci, L.; Loidl, P.; Brosch, G. Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides J. Med. Chem. 2005, 48, 3344-3353
51. Mai, A.; Massa, S.; Pezzi, R.; Rotili, D.; Loidl, P.; Brosch, G. Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A J. Med. Chem. 2003, 46, 4826-4829
52. Lobera, M.; Madauss, K. P.; Pohlhaus, D. T.; Wright, Q. G.; Trocha, M.; Schmidt, D. R.; Baloglu, E.; Trump, R. P.; Head, M. S.; Hofmann, G. A.; Murray-Thompson, M.; Schwartz, B.; Chakravorty, S.; Wu, Z.; Mander, P. K.; Kruidenier, L.; Reid, R. A.; Burkhart, W.; Turunen, B. J.; Rong, J. X.; Wagner, C.; Moyer, M. B.; Wells, C.; Hong, X.; Moore, J. T.; Williams, J. D.; Soler, D.; Ghosh, S.; Nolan, M. A. Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group Nat. Chem. Biol. 2013, 9, 319-325
53. Verma, R. P. Hydroxamic acids as matrix metalloproteinase inhibitors EXS 2012, 103, 137-176
54. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank Nucleic Acids Res. 2000, 28, 235-242
55. Vannini, A.; Volpari, C.; Gallinari, P.; Jones, P.; Mattu, M.; Carfi, A.; De Francesco, R.; Steinkuhler, C.; Di Marco, S. Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8-substrate complex EMBO Rep. 2007, 8, 879-884
56. Bressi, J. C.; Jennings, A. J.; Skene, R.; Wu, Y.; Melkus, R.; De Jong, R.; O'Connell, S.; Grimshaw, C. E.; Navre, M.; Gangloff, A. R. Exploration of the HDAC2 foot pocket: synthesis and SAR of substituted N -(2-aminophenyl) benzamides Bioorg. Med. Chem. Lett. 2010, 20, 3142-3145
57. Schuetz, A.; Min, J.; Allali-Hassani, A.; Schapira, M.; Shuen, M.; Loppnau, P.; Mazitschek, R.; Kwiatkowski, N. P.; Lewis, T. A.; Maglathin, R. L.; McLean, T. H.; Bochkarev, A.; Plotnikov, A. N.; Vedadi, M.; Arrowsmith, C. H. Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity J. Biol. Chem. 2008, 283, 11355-11363
58. Dowling, D. P.; Gantt, S. L.; Gattis, S. G.; Fierke, C. A.; Christianson, D. W. Structural studies of human histone deacetylase 8 and its site-specific variants complexed with substrate and inhibitors Biochemistry 2008, 47, 13554-13563
59. Corey, E. J.; CHaykovsky, M. Dimethylsulfoxonium methylide J. Am. Chem. Soc. 1962, 84, 867-868
60. 2). Formation and application to organic synthesis J. Am. Chem. Soc. 1965, 87, 1353-1364
61. Corey, E. J.; Jautelat, M. Construction of ring systems containing the gemdimethylcyclopropane unit using diphenylsulfonium isopropylide J. Am. Chem. Soc. 1967, 89, 3912-3914
62. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004, 9, 430-431
63. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discovery 2007, 6, 881-890
64. Wu, H.; Du, L. M. Spectrophotometric determination of anilines based on charge-transfer reaction Spectrochim. Acta, Part A 2007, 67, 976-979
65. Mulder, G. J.; Meerman, J. H. Sulfation and glucuronidation as competing pathways in the metabolism of hydroxamic acids: the role of N,O-sulfonation in chemical carcinogenesis of aromatic amines Environ. Health Perspect. 1983, 49, 27-32
66. Obach, R. S. Potent inhibition of human liver aldehyde oxidase by raloxifene Drug Metab. Dispos. 2004, 32, 89-97
67. Tang, H.; Macpherson, P.; Marvin, M.; Meadows, E.; Klein, W. H.; Yang, X. J.; Goldman, D. A histone deacetylase 4/myogenin positive feedback loop coordinates denervation-dependent gene induction and suppression Mol. Biol. Cell 2009, 20, 1120-1131
68. Sivaguru, J.; Sunoj, R. B.; Wada, T.; Origane, Y.; Inoue, Y.; Ramamurthy, V. Enhanced diastereoselectivity via confinement: diastereoselective photoisomerization of 2,3-diphenyl-1-benzoylcyclopropane derivatives within zeolites J. Org. Chem. 2004, 69, 5528-5536
69. Martin, S. F.; Austin, R. E.; Oalmann, C. J.; Baker, W. R.; Condon, S. L.; deLara, E.; Rosenberg, S. H.; Spina, K. P.; Stein, H. H.; Cohen, J. 1,2,3-Trisubstituted cyclopropanes as conformationally restricted peptide isosteres: application to the design and synthesis of novel renin inhibitors J. Med. Chem. 1992, 35, 1710-1721
70. Doyle, M. P.; Loh, K.-L.; DeVries, K. M.; Chinn, M. S. Enhancement of stereoselectivity in catalytic cyclopropanation reactions Tetrahedron Lett. 1987, 28, 833-836